Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.65
$0.03
$2.09
$857K0.22513,448 shs53.64 million shs
Cue Health Inc. stock logo
HLTH
Cue Health
$0.04
-29.8%
$0.07
$0.04
$0.74
$6.91M1.0913.38 million shs96.00 million shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.10
$0.28
$0.01
$6.17
$180K0.966,820 shsN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$1.75
$1.53
$1.04
$9.35
$3.19M1.32,805 shs3 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%-96.18%-96.51%
Cue Health Inc. stock logo
HLTH
Cue Health
0.00%0.00%0.00%0.00%0.00%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%+100.00%+769.57%-74.36%-97.36%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.00%+24.11%+24.11%+0.57%-78.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Cue Health Inc. stock logo
HLTH
Cue Health
N/AN/AN/AN/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
4.00
Strong BuyN/AN/A
Cue Health Inc. stock logo
HLTH
Cue Health
0.00
N/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$11.70M0.00N/AN/A($1.37) per share0.00
Cue Health Inc. stock logo
HLTH
Cue Health
$70.94M0.10N/AN/A$1.62 per share0.03
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share0.71
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$300K10.63N/AN/A$37.95 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/A
Cue Health Inc. stock logo
HLTH
Cue Health
-$373.46M-$2.44N/AN/AN/A-526.48%-67.82%-53.79%N/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%8/5/2025 (Estimated)
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-$62.01M-$28.02N/AN/AN/A-79.74%-57.16%8/18/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Cue Health Inc. stock logo
HLTH
Cue Health
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
1.50
1.34
Cue Health Inc. stock logo
HLTH
Cue Health
N/A
2.54
2.22
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/A
7.76
7.76

Institutional Ownership

CompanyInstitutional Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
Cue Health Inc. stock logo
HLTH
Cue Health
45.49%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
43.77%

Insider Ownership

CompanyInsider Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
43.60%
Cue Health Inc. stock logo
HLTH
Cue Health
12.50%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
46.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
22025.21 million14.13 millionOptionable
Cue Health Inc. stock logo
HLTH
Cue Health
726159.09 million139.21 millionOptionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
2601.82 million984,000No Data

Recent News About These Companies

Talis Biomedical Corp Ordinary Shares
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
(TLIS) Trading Report
Talis Biomedical Corp (TLIS)
Talis Biomedical Corporation (TLIS)
TLIS Feb 2024 2.500 put
LICY, BTAI and HROW among mid-day movers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Accelerate Diagnostics stock logo

Accelerate Diagnostics NASDAQ:AXDX

$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Cue Health stock logo

Cue Health NASDAQ:HLTH

Cue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.10 0.00 (0.00%)
As of 06/20/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Talis Biomedical stock logo

Talis Biomedical NASDAQ:TLIS

$1.75 0.00 (0.00%)
As of 06/20/2025

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.